What To Know
- “We are delighted to welcome George to the senior leadership team as we are poised to build on the momentum of the past year,” said Daphne Zohar, Founder and Chief Executive Officer of PureTech.
- “PureTech has built a leadership position in the science of the brain-immune-gut axis, which has led to the discovery and development of novel medicines.
January 5, 2021
George Farmer, Ph.D. is the new chief financial officer at PureTech. Dr. Farmer will be responsible for all aspects of the Company’s finances, including capital markets strategy and execution, strategic and financial planning, and financial reporting.
“We are delighted to welcome George to the senior leadership team as we are poised to build on the momentum of the past year,” said Daphne Zohar, Founder and Chief Executive Officer of PureTech. “This is an important moment for PureTech, as we recently initiated three clinical trials based on programs from our Wholly Owned Pipeline and expanded our presence with the NASDAQ Global Market listing. We believe that George’s depth of experience will be very helpful as we share the PureTech story with a broader community of investors.”
Dr. George Farmer joins PureTech from BMO Capital Markets where he completed a 15-year career as a senior biotechnology equity analyst providing in-depth sector research for institutional investor clients. Prior to this role, Dr. Farmer served as Chief Executive Officer of Cortice Biosciences, a privately held biotechnology company focused on the clinical development of therapies for brain malignancies and neurodegenerative diseases. He also served as Vice President of Corporate Development at Synta Pharmaceuticals, a publicly traded company developing cancer therapeutics. Dr. Farmer was a postdoctoral fellow at Sloan Kettering Cancer Center and University of California San Francisco after receiving his Ph.D. in Biological Sciences from Columbia University and a B.A. from Dartmouth College.
“PureTech has built a leadership position in the science of the brain-immune-gut axis, which has led to the discovery and development of novel medicines. I am particularly intrigued by the potential of LYT-100 for treating multiple fibrotic diseases and LYT-200 as a potential new cancer immunotherapeutic. Just as impressive is the track record of management, which has developed a deep therapeutic pipeline both internally and through the Company’s Founded Entities,” Dr. George Farmer said. “I am very excited to become a member of the PureTech team.”